GSTP1 and non-small cell lung carcinoma: An in vitro study demonstrated that enzyme activity in a GSTP1 variant, Val105, was reduced by 80% [54], and this variant exhibited better survival than the wild type genotype in patients with non-small-cell lung carcinoma after platinum-based chemotherapy [55,56].